---

Mrs. Vanitha | 43F | Mani Hospital - Report Interpretation & Management

---

SUMMARY OF KEY ABNORMALITIES

---

1. ECHOCARDIOGRAM INTERPRETATION

Structural Findings

• LV dimensions (LVID-d 42 mm, LVID-s 28 mm): Normal LV size, no dilatation.
• IVS and LVPW both at 11 mm diastole: At the upper limit of normal - borderline concentric remodeling, likely hypertensive/diabetic cardiomyopathy in context.
• Left Atrium: 40 mm - at the upper limit of normal; consistent with early LA enlargement from diastolic dysfunction.
• EF 63%, FS 33%: Normal systolic function (preserved EF).
• No RWMA: No evidence of ischemia at rest.

Functional Findings

• Grade 1 Diastolic Dysfunction (impaired relaxation): Earliest stage - LV relaxation is impaired but filling pressures are still normal. Typically seen in hypertension, diabetes, aging, and hypertrophic states. Associated with E/A ratio < 0.8 and prolonged deceleration time (values not filled, but Grade 1 impression given).
• Mild Mitral Regurgitation (MR mild): Seen on color Doppler (last image). In context of Grade 1 DD, likely functional MR from suboptimal LV relaxation rather than structural valve disease.
• Aortic and pulmonary valve gradients normal (4 mmHg peak, 1 m/s velocity).

Echo Interpretation Summary

HFpEF precursor pattern - Normal systolic function with Grade 1 diastolic dysfunction and mild MR in a diabetic, dyslipidemic patient. Cardiac structural adaptation to metabolic stress. Cardiologist referral appropriately recommended.

---

2. CBC INTERPRETATION

• Hb 11.3 with HCT 30.6% and MCV 76.3: Borderline iron deficiency anemia / nutritional anemia pattern. In a 43-year-old female (perimenopausal age), menstrual losses are a common contributing factor.
• All other CBC parameters normal.

---

3. BIOCHEMISTRY INTERPRETATION

Diabetes - POORLY CONTROLLED

• HbA1c 10.5% (normal < 6.5%): Reflects average blood glucose of ~256 mg/dL over past 3 months. This represents poor glycemic control and significantly elevates cardiovascular, renal, and retinal risk.

Lipid Profile - SEVERELY DYSLIPIDEMIC (Mixed Dyslipidemia)

Renal Function

• Creatinine 1.3 mg/dL (ref 0.7-1.1): Mildly elevated - early diabetic nephropathy possible. Urea 24 mg/dL is normal.
• eGFR should be calculated (using CKD-EPI): For a 43F, Cr 1.3 - estimated eGFR ~51-55 mL/min/1.73m² (CKD Stage G3a range - needs confirmation).
• Urine microalbumin/creatinine ratio should be checked to assess for diabetic nephropathy.

Liver Function - NORMAL

• AST 9, ALT 17, Total Bilirubin 0.9, Albumin 4.6, Total Protein 8.0 - all within normal limits. Liver function preserved despite dyslipidemia and diabetes.

Electrolytes/ABG - NORMAL

• Na 139, K 4.9, Cl 98, HCO3 24, pH 7.4, PCO2 30: All within normal limits. No acid-base disturbance. Note PCO2 at low-normal 30 may reflect mild hyperventilation but not clinically significant here.

ESR: 17 mm/hr - Normal.

---

MANAGEMENT PLAN

PRIORITY 1: GLYCEMIC CONTROL (URGENT)

• Metformin (if eGFR > 45): 500 mg twice daily, uptitrate to 1000 mg BD. Hold if eGFR <45 or planned contrast study.
• Add SGLT2 inhibitor (Empagliflozin 10 mg or Dapagliflozin 10 mg OD): Provides glycemic control + cardioprotection (reduces HFpEF events, slows CKD progression) - ideal in this patient given diastolic dysfunction and mild CKD.
• Consider GLP-1 RA (Semaglutide 0.5 mg weekly SC) if further control needed - also cardioprotective and aids weight loss.
• If HbA1c does not improve within 3 months, basal insulin (Glargine 10 units bedtime) may be added.
• Target HbA1c: <7.0% (< 7.5% given cardiovascular disease markers).
• Diabetic diet counseling: carbohydrate restriction, avoid sugary foods/refined grains.

PRIORITY 2: DYSLIPIDEMIA (HIGH RISK - REQUIRES AGGRESSIVE TREATMENT)

• High-intensity statin: Rosuvastatin 20-40 mg at night OR Atorvastatin 40-80 mg at night. This is the first-line agent for LDL lowering.
• Triglycerides 443 mg/dL: Requires treatment. Once TG > 500, pancreatitis risk is significant.
  • Fenofibrate 145 mg OD (or Omega-3 fatty acids 2-4 g/day) for TG lowering.
  • Correcting hyperglycemia itself will substantially lower TG.
  • Strict dietary fat restriction.
• Recheck fasting lipid profile after 3 months of treatment.

PRIORITY 3: RENAL PROTECTION

• Confirm eGFR with formal CKD-EPI calculation.
• Check spot urine ACR (albumin-to-creatinine ratio) to screen for diabetic nephropathy.
• If microalbuminuria confirmed, start/continue ACE inhibitor or ARB (e.g., Telmisartan 40 mg OD) - renoprotective and also helps with diastolic dysfunction/hypertension.
• SGLT2 inhibitor (above) provides independent renoprotection.
• Avoid NSAIDs and nephrotoxic drugs.
• Repeat creatinine in 3 months.

PRIORITY 4: CARDIAC MANAGEMENT

• Cardiologist referral as recommended on echo report.
• Grade 1 diastolic dysfunction with mild MR: No specific anti-heart-failure drugs needed yet, but cardiovascular risk factor control (DM, dyslipidemia, BP) is the primary treatment.
• Check blood pressure - if hypertensive (likely, given IVS/LVPW upper limit), start ACE-i/ARB as above which treats both HTN and diastolic dysfunction.
• Mild MR: No intervention needed; annual echo follow-up.
• Rule out hypertension as a co-contributor - monitor BP at each visit.
• Repeat echo in 1 year to monitor diastolic function grade.
• Screen for CAD with stress test if symptomatic (chest pain, exertional dyspnea).

PRIORITY 5: ANEMIA

• Iron studies (serum iron, TIBC, ferritin) to confirm iron deficiency anemia.
• If confirmed: Ferrous sulfate 200 mg OD/BD for 3 months, re-check CBC.
• Gynecological evaluation for menorrhagia if relevant.

LIFESTYLE MODIFICATIONS (All conditions)

• Diet: Diabetic, heart-healthy diet (low glycemic index, low saturated fat, low simple sugars, high fiber). Reduce refined carbohydrates to address both DM and TG.
• Exercise: Moderate aerobic activity 30-45 min, 5 days/week (walking, cycling) - improves insulin resistance, reduces TG, improves diastolic function.
• Weight management: Target BMI < 23 (Asian guidelines).
• Smoking/alcohol cessation if applicable.
• Restrict dietary fat - especially important with TG 443.

FOLLOW-UP INVESTIGATIONS RECOMMENDED

---

DIAGNOSTIC SUMMARY

1. Uncontrolled Type 2 Diabetes Mellitus (HbA1c 10.5%)
2. Mixed hyperlipidemia - severe hypertriglyceridemia (443 mg/dL) + high LDL (215 mg/dL)
3. Cardiac involvement - Grade 1 diastolic dysfunction with mild MR (early diabetic/hypertensive cardiomyopathy)
4. Early renal impairment - creatinine 1.3 (likely early diabetic nephropathy)
5. Borderline iron deficiency anemia

Disclaimer: This interpretation is for educational/clinical reference. All treatment decisions must be made by the treating physician after full clinical assessment.